Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Moderna, Inc. (MRNA) Price & Performance

GlobalFoundries Inc. Ordinary SharesTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

GlobalFoundries Inc. Ordinary Shares vs Moderna, Inc. — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $50.48 (market cap $26.80B), while Moderna, Inc. trades at $195.7 (market cap $78.44B). The key difference: Moderna, Inc. is far larger — about 2.9× GlobalFoundries Inc. Ordinary Shares's market cap, and GlobalFoundries Inc. Ordinary Shares pays a 1% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and Moderna, Inc. for 59 Days on average.

GFSMRNA
Market Cap
$26.80B$78.44B
Volume
2,967,33714,597,511
Sector
TechnologyHealth
52-Week High
$89.96$203.46
52-Week Low
$32.24$22.36
Typical Hold Time
0 Days59 Days
Enterprise Value
$26.09B$74.59B
Dividend Yield
1%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GlobalFoundries Inc. Ordinary Shares

No Aura AI signal available yet.

Moderna, Inc.

Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.

Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GFS
51% Buy49% Sell
Avg holding period · 0 Days
MRNA
29% Buy71% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About GlobalFoundries Inc. Ordinary Shares

GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.

Read more on GFS →

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA →